Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04972227 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia
A Phase 1 study, sponsored by Tisento Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT04972227 is a Phase 1 study that has completed, run by Tisento Therapeutics. The registered enrollment target is 48 participants.
The verdict
NCT04972227, a Phase 1 study, has completed, sponsored by Tisento Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of CY6463 when administered to participants with stable schizophrenia who are on a stable antipsychotic medication regimen
Interventions
- DRUG Placebo
- DRUG CY6463
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2021-09-10 |
| Est. Completion | 2022-04-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04972227
The ClinicalTrials.gov registry entry for NCT04972227 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tisento Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04972227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04972227 about?
NCT04972227 is a clinical study titled "Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia". The primary objective of this study is to evaluate the safety and tolerability of CY6463 when administered to participants with stable schizophrenia who are on a stable antipsychotic medication regimen
What is the current status of trial NCT04972227?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2021-09-10. Estimated completion is 2022-04-18.
What interventions are being tested in trial NCT04972227?
The interventions under investigation include: Placebo (DRUG), CY6463 (DRUG).
Who is sponsoring clinical trial NCT04972227?
This trial is sponsored by Tisento Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.